Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRBC1 CAR-T Cell Therapy in Relapsed/Refractory TRBC1 Positive T Cell Hematological Malignancies
NCT04828174Phase 1Suspended
- Sponsor
- Shanghai General Hospital
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-TRBC1 CAR-T cell therapy in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and 2 more, sponsored by Shanghai General Hospital. Primary endpoint: Safety and Tolerability at 28 days. Started Mar 2021; status: suspended.
02
Drugs
anti-TRBC1 CAR-T cell therapy
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)T-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04828174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828174.